Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients

• Verfasst von: Tomasik, Jakub [VerfasserIn]
• Verfasst von: Leweke, F. Markus [VerfasserIn]
• Titel: Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients
• Verf.angabe: Jakub Tomasik, Emanuel Schwarz, Santiago G. Lago, Matthias Rothermundt, F. Markus Leweke, Nico J.M. van Beveren, Paul C. Guest, Hassan Rahmoune, Johann Steiner, Sabine Bahn
• Jahr: 2016
• Jahr des Originals: 2015
• Umfang: 9 S.
• Fussnoten: Gesehen am 08.02.2019 ; Available online 2 November 2015
• Titel Quelle: Enthalten in: Brain, behavior and immunity
• Ort Quelle: Orlando, Fla. [u.a.] : Elsevier, 1987
• Jahr Quelle: 2016
• Band/Heft Quelle: 52(2016), Seite 178-186
• ISSN Quelle: 1090-2139
• DOI: doi:10.1016/j.bbi.2015.10.019
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Schizophrenia
• Sach-SW: Olanzapine
• Sach-SW: Biomarker
• Sach-SW: CD36
• Sach-SW: FABP3
• Sach-SW: Personalised medicine
• K10plus-PPN: 1587405369

Abstract

Traditional schizophrenia pharmacotherapy remains a subjective trial and error process involving administration, titration and switching of drugs multiple times until an adequate response is achieved. Despite this time-consuming and costly process, not all patients show an adequate response to treatment. As a consequence, relapse is a common occurrence and early intervention is hampered. Here, we have attempted to identify candidate blood biomarkers associated with drug response in 121 initially antipsychotic-free recent-onset schizophrenia patients treated with widely-used antipsychotics, namely olanzapine (n=40), quetiapine (n=23), risperidone (n=30) and a mixture of these drugs (n=28). Patients were recruited and investigated as two separate cohorts to allow biomarker validation. Data analysis showed the most significant relationship between pre-treatment levels of heart-type fatty acid binding protein (H-FABP) and response to olanzapine (p=0.008, F=8.6, β=70.4 in the discovery cohort and p=0.003, F=15.2, β=24.4 in the validation cohort, adjusted for relevant confounding variables). In a functional follow-up analysis of this finding, we tested an independent cohort of 10 patients treated with olanzapine and found that baseline levels of plasma H-FABP and expression of the binding partner for H-FABP, fatty acid translocase (CD36), on monocytes predicted the reduction of psychotic symptoms (p=0.040, F=6.0, β=116.3 and p=0.012, F=11.9, β=-0.0054, respectively). We also identified a set of serum molecules changed after treatment with antipsychotic medication, in particular olanzapine. These molecules are predominantly involved in cellular development and metabolism. Taken together, our findings suggest an association between biomarkers involved in fatty acid metabolism and response to olanzapine, while other proteins may serve as surrogate markers associated with drug efficacy and side effects.